-
Reports of falsified Ozempic pens
Reports of falsified Ozempic pens
-
Reports of falsified Ozempic pens
Reports of falsified Ozempic pens
EMA alerts EU patients and healthcare professionals that pre-filled pens falsely labelled as the diabetes medicine Ozempic have been identified at wholesalers in EU and the UK
-
CHMP Highlights: October 2023
CHMP Highlights: October 2023
-
CHMP Highlights: October 2023
CHMP Highlights: October 2023
EMA's human medicines committee (CHMP) recommended 7 new medicines for approval in the EU at its October 2023 meeting
-
Management Board: Highlights of October 2023 meeting
Management Board: Highlights of October 2023 meeting
-
Management Board: Highlights of October 2023 meeting
Management Board: Highlights of October 2023 meeting
The Board adopted revised transparency rules for the Clinical Trials Information System and was updated on EMA’s activities in the first half of 2023
-
Revision of transparency rules for clinical trials
Revision of transparency rules for clinical trials
-
Revision of transparency rules for clinical trials
Revision of transparency rules for clinical trials
EMA revised rules to give faster access to information in the EU Clinical Trials Information System
Information for you
Key content
Services & databases
-
List item
Clinical Trials website
-
List item
Account Management portal
-
List item
eSubmission
-
List item
EudraVigilance (human)
-
List item
EudraVigilance Veterinary
-
List item
Veterinary Medicines information website
-
List item
Suspected adverse drug reactions database
-
List item
Clinical data
-
List item
SPOR data management services
-
List item
Service Desk
-
List item
IRIS platform
-
List item
Public register of parallel distribution notices
-
List item
European Vaccination Information Portal